Author: Jian Jun knowHealth Bureau
On July 7th, Berry's "Technology for the Future Unlimited" product launch conference was held in Beijing, and announced that the scope of its NextSeq CN500 gene sequencer has been changed, becoming a medical institution that can be landed, and can directly carry out large-scale clinical genes. Detected NGS (next generation sequencing) universal platform.
It is understood that the scope of the change of the NextSeq CN500 gene sequencer is for human DNA sequencing (DNA) sequencing to detect gene sequences, which may lead to disease or susceptibility. The instrument can be used clinically in conjunction with the in vitro diagnostic reagents approved by the National Drug Administration and the random software associated with the instrument, and is not used for human genome sequencing or de novo sequencing.
▲Berry Gene Chairman Gao Yang
“Compared with research, clinical applications have more unique requirements for gene sequencers.” Gao Yang, chairman of Berry Gene, explained that due to the characteristics of clinical scenes, genetic sequencers only have simple operation, large throughput, and high data quality. When the cost of detection is low, it can be adopted by medical institutions on a large scale. This is why there are many genetic sequencers on the market, but few are actually accepted by frontline medical institutions.
According to the Knowledge Bureau, the scope of application of the NextSeq CN500 has been greatly expanded, which means that clinical genetic testing has entered more disease fields across NIPT. What is more worthy of expectation is that this platform can be used in clinical, scientific research, and multi-disciplinary fields in the future. In terms of bringing great social and economic value to society and families. This is the target market for Berry's genes.
高阳说，整个产业链布局是Berry Gene的发展战略。 NextSeq CN500的扩容获得批准，这加强了Berry在产业链上游建立基因检测平台的目标，并提前规划了大型泛市场。为晚期肿瘤提供临床检测服务，加快肿瘤早期诊断和早期筛查的研究和开发，加快大面板的研发，并开展更多合作。
According to Piper Jaffray, a well-known investment bank, by 2026, liquid biopsy with genetic testing technology as the core will reach a global market size of $32.6 billion, including $28.6 billion in cancer and $2 billion in non-invasive prenatal diagnosis (NIPT).
This will mean that the market for genetic testing in the field of tumors is more than ten times larger than that of NIPT. According to this ratio, as the NextSeq CN500 breaks through the limitations of the NIPT field, it enters a wider range of applications such as tumor detection. Will achieve geometric growth.xx